{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_metadata=all&version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?version=2&hansardHeading=Non-tuberculous+Mycobacteria%3A+Medical+Treatments", "items" : [{"_about" : "http://data.parliament.uk/resources/1521761", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1521761/answer", "answerText" : {"_value" : "<p>On 20 October 2022, NHS England published clinical commissioning policy on the use of nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease NTMPD, following an independent review. NHS England concluded that there was enough evidence to make the treatment available.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-08-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1521761/answer/previousversion/25107", "answeringMember" : "http://data.parliament.uk/members/4592", "answeringMemberConstituency" : {"_value" : "Sleaford and North Hykeham"}
          , "answeringMemberPrinted" : {"_value" : "Dr Caroline Johnson"}
        }
        , "questionFirstAnswered" : [{"_value" : "2023-08-22T08:06:30.753Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Non-tuberculous Mycobacteria: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of access to innovative treatments for people living with non-tuberculosis mycobacteria in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"}
      }
      , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"}
      , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"}
      ], "uin" : "62682"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}